Clinical Trial Update: This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. [Phase 3]

View source ↗

Summary

Phase 3 trial investigating whether combining Mevrometostat (PF-06821497) with enzalutamide improves outcomes versus enzalutamide alone in ARPI-naïve metastati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-sensitive Prostate Cancer
• Hormone Sensitive Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Enzalutamide (enzalutamide)
• Mevrometostat (Mevrometostat)

Snippet

Sponsor: Pfizer | Conditions: Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer | Phase 3 | Status: RECRUITING